Biotech Startups
9,909 companies tagged Biotech, with their investors and founders.
EditForce develops proprietary PPR gene-editing technology that can modify both DNA and RNA, with applications in medicine, agriculture, and chemical industries. The company aims to advance therapeutic drug development and address challenges in health, food, and environmental sectors.
3 investors
Endo-Phyte develops agricultural practices using endophytic fungi (Dark Septate Endophytes) to improve crop yields and soil health. The company serves agricultural producers and focuses on sustainable, regenerative farming methods in the agtech sector.
3 investors
ThinkCyte develops diagnostic devices and cellular analysis platforms using imaging flow cytometry and microfluidics technology. The company serves research institutions, clinical laboratories, and biopharmaceutical companies in the life sciences and diagnostic tools sector.
3 investors
Rege Nephro develops regenerative medicine therapies for kidney disease, focusing on nephron progenitor cell research and differentiation from iPS cells. The company aims to commercialize treatments for patients with kidney disorders and reduce reliance on dialysis and transplantation.
3 investors
LiberoThera is a drug discovery company using cell-free membrane protein preparation technology and non-natural amino acid incorporation technology to develop antibody-based therapeutics, including antibodies targeting GPCRs such as anti-CCR8. It operates through research alliances and partnerships in the biopharmaceutical field.
3 investors
Buzzreach is a Japanese startup that builds SaaS platforms connecting pharmaceutical companies and medical institutions with patients to support clinical trials and post-launch marketing. It promotes a "DRO" (Digital Research Organization) model using patient-matching via electronic medical records, AI-generated trial documents, decentralized clinical trials, and a patient-centric social network called "miilike."
3 investors
Digzyme develops novel enzymes and bioprocesses to order, providing enzyme libraries, sample supply, IP licensing, and support for scale-up, commercialization, and regulatory approvals. It serves industrial clients seeking custom enzyme solutions in the biotech sector.
3 investors
Gaudi Clinical is a Japanese company in the clinical and cellular field. Based on the company outline page, it appears to operate in cellular or clinical biotech, though the page does not explicitly detail specific products or services.
3 investors
StemRIM is a biopharmaceutical company developing regenerative medicine therapies. It is listed on the Tokyo Stock Exchange Growth Market (ticker 4599).
3 investors
Fermenstation develops and manufactures ethanol and food ingredients from food waste and other unused biomass through fermentation, and provides OEM/ODM production of cosmetics and sundry goods. Based in Japan, it also pursues co-creation businesses using unused resources.
3 investors
Enu Pharma (遠友ファーマ) is a biotech startup developing antibody drugs with high selectivity based on a glycopeptide-targeting method discovered at Hokkaido University. The company aims to create new drug targets and therapies for patients with various diseases.
3 investors
Digital Blast develops satellite and space technology solutions. The company supports Japan's space industry through workforce development initiatives in partnership with non-profit organizations.
2 investors
Reprocell is a biotechnology company that manufactures and sells iPS cell-related research reagents, provides drug discovery support services including iPS cell establishment and CRO services, and offers clinical testing and regenerative medicine product development.
2 investors
10x Science provides an AI platform that automates protein characterization for drug developers, reducing months of manual analysis to speed the evaluation of therapeutic candidates in early-stage development.
2 investors
1910 develops an AI platform that integrates multimodal data, frontier AI models, and high-throughput lab automation to accelerate drug discovery and development for pharmaceutical companies. The platform targets undruggable targets and aims to improve R&D productivity in the biopharma industry.
2 investors
20/20 BioLabs develops AI-powered blood tests for early detection of multiple cancers and chronic diseases, using protein tumor markers and machine learning. The company offers affordable, at-home collection tests starting under $200, targeting individuals and healthcare providers seeking early disease detection.
2 investors
310 AI develops generative AI foundation models for biology, including a molecular programming model that generates protein sequences from text descriptions of protein function. The company works toward making programmable biology a practical tool for solving real-world problems.
2 investors
35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need. The company combines scientific expertise with operational efficiency to advance complex therapies from early discovery through clinical validation.
2 investors
3Dnamics engineers 3D organoid models from human stem cells to develop therapeutics for neurological diseases including Alzheimer's and Parkinson's. The company serves pharmaceutical and biotech research sectors developing novel treatments.
2 investors
4TEEN4 develops monoclonal antibody therapeutics targeting shock and critical illness in patients. The company is advancing invobenitug (procizumab), a first-in-class treatment designed to address circulating dipeptidyl peptidase 3, a molecular driver of cardiovascular dysfunction and organ failure in shock states.
2 investors
5AM Ventures is an investment firm with professionals holding expertise in science, medicine, operations, legal, and finance who identify and develop life science portfolio companies.
2 investors
A clinical-stage biopharmaceutical company developing investigational therapies for patients with liver and cardiometabolic diseases, with a lead candidate (pegozafermin) being evaluated for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
2 investors
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications. The company targets cancer and other serious diseases, advancing its cell therapies through clinical trials.
2 investors
A51 develops a technology platform for programming RNA molecules to control cell behavior. The company operates in the biotech/synthetic biology sector.
2 investors